Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540894 | 0.89 | GPR119 (0.50) | GPR119CHEK1SCDARNR3C1 | |
| SCHEMBL12234553 | 0.89 | GPR119 (0.42) | GPR119AR | |
| SCHEMBL12234591 | 0.88 | GPR119 (0.49) | GPR119CHEK1SCD | |
| SCHEMBL1549889 | 0.85 | GPR119 (0.55) | GPR119SCD | |
| SCHEMBL2540198 | 0.85 | GPR119 (0.51) | GPR119CHEK1SCD | |
| SCHEMBL2547658 | 0.84 | GPR119 (0.67) | GPR119 | |
| SCHEMBL14693050 | 0.79 | GPR119 (0.50) | GPR119SCD | |
| SCHEMBL12234552 | 0.79 | GPR119 (0.45) | GPR119 | |
| SCHEMBL12234567 | 0.78 | GPR119 (0.40) | GPR119SCD | |
| SCHEMBL14693056 | 0.78 | GPR119 (0.59) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8372837-B2 | Pyridone and pyridazone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | GPR119 1/4885CHEK1 3049/4885SCD 4268/4885 |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | GPR119 1/4885CHEK1 3030/4885SCD 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.